Background & Objective: Aptamers are single-stranded DNA or RNA oligonucleotides
generated by a novel in vitro selection technique termed Systematic evolution of ligands by exponential
enrichment (SELEX). During the past two decades, various aptamer drugs have been developed
and many of them have entered into clinical trials.
Conclusion: In the present review, we focus on aptamers as potential therapeutics for hematological
diseases, including anemia of chronic inflammation (ACI) and anemia of chronic disease (ACD), hemophilia,
thrombotic thrombocytopenic purpura (TTP) or VWD type-2B, and sickle cell disease
(SCD), in particular, those that have entered into clinical trials.